Stock Scorecard



Stock Summary for GRAIL Inc (GRAL) - $66.57 as of 6/26/2026 2:50:59 PM EST

Total Score

9 out of 30

Safety Score

30 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for GRAL

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GRAL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GRAL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for GRAL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for GRAL (30 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for GRAL

GRAIL Inc Actuals & Estimates (BIVA:GRAL) 6/26/2026 6:39:00 PM
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm 6/26/2026 2:39:00 PM
GRAIL Secures $110 Million Investment from Samsung 6/26/2026 1:39:00 PM
Recover Investment Losses: Class Action Initiated Against GRAIL, Inc. (GRAL) 6/26/2026 3:11:00 AM
GRAIL, Inc. announced that it has received $110.000075 million in funding from Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd., Samsung C&T Corporation 6/25/2026 8:11:00 PM
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Grail, Inc. (GRAL) to Contact Law Firm 6/25/2026 6:11:00 PM
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Grail, Inc. (GRAL) to Contact Law Firm 6/25/2026 6:11:00 PM
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm 6/25/2026 4:11:00 PM
Grail, Inc. (GRAL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit 6/25/2026 4:11:00 PM
GRAIL Closes $110 Million Equity Investment From Samsung to Support Global Expansion 6/25/2026 4:11:00 PM

Financial Details for GRAL

Company Overview

Ticker GRAL
Company Name GRAIL Inc
Country USA
Description GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
Sector Name HEALTHCARE
Industry Name DIAGNOSTICS & RESEARCH
Most Recent Quarter 3/31/2026
Next Earnings Date 8/11/2026

Stock Price History

Last Day Price 66.57
Price 4 Years Ago 0.00
Last Day Price Updated 6/26/2026 2:50:59 PM EST
Last Day Volume 605,378
Average Daily Volume 782,963
52-Week High 118.84
52-Week Low 29.95
Last Price to 52 Week Low 122.27%

Valuation Measures

Trailing PE N/A
Industry PE 33.23
Sector PE 78.54
5-Year Average PE -15.24
Free Cash Flow Ratio 41.09
Industry Free Cash Flow Ratio 34.07
Sector Free Cash Flow Ratio 28.63
Current Ratio Most Recent Quarter 11.74
Total Cash Per Share 1.62
Book Value Per Share Most Recent Quarter 60.79
Price to Book Ratio 1.11
Industry Price to Book Ratio 5.12
Sector Price to Book Ratio 10.60
Price to Sales Ratio Twelve Trailing Months 18.30
Industry Price to Sales Ratio Twelve Trailing Months 5.14
Sector Price to Sales Ratio Twelve Trailing Months 24.91
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 42,916,600
Market Capitalization 2,856,958,062
Institutional Ownership 83.57%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 79.85%
Reported EPS 12 Trailing Months -10.30
Reported EPS Past Year -1.37
Reported EPS Prior Year -11.18
Net Income Twelve Trailing Months -395,325,000
Net Income Past Year -408,351,000
Net Income Prior Year -2,027,005,000
Quarterly Revenue Growth YOY 28.10%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -332.90%

Balance Sheet

Total Cash Most Recent Quarter 69,344,000
Total Cash Past Year 249,727,000
Total Cash Prior Year 214,234,000
Net Cash Position Most Recent Quarter 69,344,000
Net Cash Position Past Year 249,727,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 2,577,862,000
Total Stockholder Equity Prior Year 2,503,405,000
Total Stockholder Equity Most Recent Quarter 2,500,686,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -293,055,000
Free Cash Flow Per Share Twelve Trailing Months -6.83
Free Cash Flow Past Year -299,916,000
Free Cash Flow Prior Year -582,364,000

Options

Put/Call Ratio 1.01
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 3.16
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 6/27/2026 12:28:42 AM EST